Acute Alcoholic Hepatitis: Clinical Trials

4 trials for Acute Alcoholic Hepatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed, 1 not yet recruiting. 4 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Terminated 2, Completed 1, Not yet recruiting 1
Phase 31Completed 1

Follow Acute Alcoholic Hepatitis: new trials by email Literature Review of Acute Alcoholic Hepatitis trials Research Report on Acute Alcoholic Hepatitis

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
MRG-001 in Patients With Alcoholic Hepatitis
MRG-001 - Alcoholic Hepatitis, Acute Alcoholic Hepatitis
Phase 2Not yet recruitingMedRegen LLC322024-09-012024-03-13
Digoxin In Treatment of Alcohol Associated Hepatitis
Intravenous digoxin - Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury
Phase 2TerminatedYale University232021-10-082026-09-29
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
IDN-6556, Placebo - Acute on Chronic Hepatic Failure, Acute Liver Failure
Phase 2TerminatedConatus Pharmaceuticals Inc.232013-09-012016-04-11
Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis
Anakinra, Pentoxifylline, Zinc Sulfate - Acute Alcoholic Hepatitis
Phase 2 / Phase 3CompletedMack Mitchell1042013-09-012021-11-01

Narrower conditions

Hepatitis, Alcoholic (3)  ·  Alcohol-Induced Disorders (1)  ·  Chemical and Drug Induced Liver Injury (1)  ·  Fatty Liver, Alcoholic (1)  ·  Fibrosis (1)  ·  Hepatitis (1)  ·  Infections (1)  ·  Liver Cirrhosis (1)  ·  Liver Diseases (1)  ·  Liver Diseases, Alcoholic (1)  ·  Liver Failure (1)  ·  Liver Failure, Acute (1)

Broader conditions

Alcohol-Related Disorders (4)  ·  Chemically-Induced Disorders (4)  ·  Digestive System Diseases (4)  ·  Substance-Related Disorders (4)  ·  Alcohol-Induced Disorders (3)  ·  Hepatitis (3)  ·  Liver Diseases (3)  ·  Liver Diseases, Alcoholic (3)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Fatty Liver (1)  ·  Hepatic Insufficiency (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)  ·  Poisoning (1)

Interventions

3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (1)  ·  Digoxin (1)  ·  Drugs, Generic (1)  ·  Interleukin 1 Receptor Antagonist Protein (1)  ·  Methylprednisolone (1)  ·  Pentoxifylline (1)  ·  Zinc Sulfate (1)

Sponsors

Conatus Pharmaceuticals Inc. (1)  ·  Mack Mitchell (1)  ·  MedRegen LLC (1)  ·  Yale University (1)

Countries

United States (3)  ·  United Kingdom (1)

Top investigators

Ali R Ahmadi, MD PhD (1)  ·  Arthur J McCullough, MD (1)  ·  Bubu Banini, MD, PhD (1)  ·  Craig J McClain, MD (1)  ·  Gyongi Szabo, MD (1)  ·  Mack C Mitchell, MD (1)  ·  Stephen Ryder, Dr. (1)

Results publications

PMID 31811953, PMID 35084335, PMID 35340032, PMID 37011138, PMID 37633275

NIH funding

U01AA021893 (1)